MAPT and Alzheimer disease: However, within the last several years, large studies using positron emission tomography (PET) to characterize the preclinical progression of AD in DS have emerged using the AT(N) (amyloid/tau/neurodegeneration) disease research framework (Jack et al., 2018; Fortea et al., 2020; Rafii et al., 2020).